### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name an Pace M	M.	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [ VRTX ]									all app Direct Offict below	olicable) ctor er (give title w)		Owner (specify )				
C/O VERTEX PHARMACEUTICALS INCORPORATED						3. Date of Earliest Transaction (Month/Day/Year) 05/02/2014									σ,	1, dorp, d.		
50 NORTHERN AVENUE						4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line)				
(Street) BOSTON MA 02210														X	Form filed by One Reporting Person  Form filed by More than One Reporting  Person			
(City) (State) (Zip)																		
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/						Execution Date,						Securities Acquired (A) or sposed Of (D) (Instr. 3, 4 ar			Secur Benef	icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount	(A) or (D)	Price	Tran		action(s) 3 and 4)		(instr. 4)
Common Stock 05/02/20					014	14			S <sup>(1)</sup>		500	D	\$67.03	)1(2)(3)		23,850	D	
Common Stock 05/02/20					014	14			S <sup>(1)</sup>		400	D	\$67.94	<b>1</b> (2)(4)	2	23,450	D	
Common Stock 05/02/20					014	14					100	D	\$69.	9.42		23,350	D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	emed ion Date, //Day/Year)	4. Transa Code ( 8)	instr.	5. Nu of Deriv Secul Acqu (A) or Dispo of (D) (Instr and 5	ative rities ired osed	Expira	ation D h/Day/		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)  Amount or Number of Title Shares				9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

### **Explanation of Responses:**

- 1. Transaction made pursuant to Ms. Pace's company approved trading plan under Rule 10b5-1.
- 2. Ms. Pace undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- $3. \ Open \ market \ sales \ reported \ on \ this \ line \ occurred \ at \ a \ weighted \ average \ price \ of \$67.01 \ (range \$66.49 \ to \$67.40).$
- 4. Open market sales reported on this line occurred at a weighted average price of \$67.94 (range \$67.73 to \$68.24).

# Remarks:

Kenneth L. Horton, Attorney-

05/06/2014

In-Fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.